Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Experimental data are presented which demomstrate the existence of a transmissible factor(s) in the majority of samples of leukemic bone marrow. This factor(s) is associated with the presence of a cytoplasmic antigen which can be detected by fixed immunofluorescence test with sera of patients with osteosarcoma, leukemia and some apparently normal individuals. Cultures of leukemic bone marrow carrying this factor(s) also form multinucleated cells when exposed to RD114 virus or cels. This factor(s) is transmitted into susceptible whole human embryo cells by cell-free culture fluid. Appearance of the new antigen can be detected by fixed immunofluorescence test about 6 weeks after transmission. Cultures showing the new antigen also form multinucleated cells following co-cultivation with RD114 virus or cells. Co-cultures of human osteosarcoma cells and leukemic bone marrow cells undergo morphologic as well as antigen changes after a long period of time (at least 3 months). Cell line fluids from these cultures contain a factor which induces in recipient whole human embryo cultures both the new antigen and morphological alterations resembling those observed in the co-cultures. Cell-free fluids from leukemic bone marrow and sarcoma cultures as well as from short-term co-cultures have failed to produce morphological alterations in whole human embryo cells. Extensive electron microscope studies carried out at different stages of the experiments have failed to reveal the presence of viral particles. The morphological changes resemble those induced in susceptible cells by sarcoma viruses. The described factor(s) may conceivably represent subviral components capable of biological activity. While suggestive of viral involvement in human sarcoma of bone and soft tissues, there is no definite proof of viruses being the causative agent(s) of human sarcoma. Present evidence provides only a basis for search of additional ways of treatment of human sarcoma to those of surgery and radiotherapy. Present treatment consists of chemotherapy as adjuvant treatment directed against viral markers represented by enzymes, nucleic acids and proteins of possible viral origin, resembling those already known to be present in animal bone and soft tissue sarcomas. However tenuous the contention of the possiblity of viral involvement in human osteosarcoma may appear, adjuvant therapy directed against viral markers warrants the attention of orthopedic surgeons and other clinicians.
 ...
PMID:Transforming factors in human sarcoma cells in tissue culture. 106 98

Sarcoma - lymphocyte-mediated cytotoxicity and serum blocking of this activity was studied by the in vitro microcytotoxicity test in three patients with osteogenic sarcoma who received preoperative irradiation. All three patients had complete histologic disappearance of the tumor between three to five months after irradiation. Lymphocyte cytotoxicity was present before and after treatment in two patients and post-treatment in one. No serum blocking activity was detected in any of these three patients. They are all alive over four years post-therapy without evidence of active disease.
 ...
PMID:Disapperance of osteogenic sarcoma after irradiation: immunologic observations. 106 52

Fourteen patients with 16 metastatic ostogenic sarcoma lesions were treated with high-dose methotrexate (HDMTX) with citrovorum factor rescue (CFR), adriamycin, and pulse high-dose cyclophosphamide combined with radiation therapy. Thirteen of 16 lesions responded. Responses consisted of relief of pain (6/6 patients) in bone lesions, roentgenographic and clinical evidence of decrease in the size of the bone lesions (6/7 patients), and a decrease in the size of pulmonary metastases (2/4 patients). The 2 patients whose pulmonary metastases responded to combined therapy developed pulmonary fibrosis and pneumonitis in the treated areas 3 months after radiation therapy (RT) (1400 and 1600 rads respectively). Of two bulky primary tumors that appeared to respond, both were ultimately found to contain viable tumor; a third less bulky primary tumor appeared to respond more completely. Three smaller metastatic bone lesions that were ultimately biopsied showed no evidence of active tumor. It is concluded that: 1) combination therapy (particularly HDMTX and RT) has an additive effect in controlling osteogenic sarcoma bone lesions, but bulky primary tumors cannot be completely eradicated; 2) although synergistic in treating osteogenic sarcoma, combination therapy can produce enhanced toxicity in surrounding normal lung tissue; and 3) combination therapy is of value in the palliative treatment of metastatic lesions other than that of lung, and in the treatment of small primary bone lesions. However, experience to date does not justify the delay in surgical ablation of a primary lesion in a child who presents without metastatic disease.
 ...
PMID:Combination chemotherapy and radiation therapy in the treatment of metastatic osteogenic sarcoma. 107 40

In a series of experiments, mainly CBA/H, but also C2H/H, mice aged 3 months were injected intraperitoneally with solutions of 90Sr Cl2, the dose per mouse varying from 7 to 20 muCi, and compared with similar mice treated with 226Ra or 239Pu, discussed elsewhere. In male mice, the commonest tumour resulting at each dose of 90Sr was non-osteogenic (angio) sarcoma, a tumour not seen after 226Ra. In females, this tumour occurred far less frequently than osteosarcoma. In CBA mice of both sexes converted to radiation chimaeras (which are sterile) and similarly treated with 90Sr, the only skeletal tumours were osteosarcomas. When only half the body of CBA mice was X-irradiated with 1000 rad and the mice given 90Sr, non-osteogenic sarcoma occurred predominantly in those mice X-irradiated in the cephalic half. The results suggest that intact testes may provide co-factors for this type of neoplasm, whereas others have shown that oestrogens facilitate murine osteosarcoma. The non-osteogenic osteosarcomas arise from damaged stromal elements in bone-marrow of selected bones. The risk to this component of bone-marrow, as well as to haematopoietic tissue, should be considered in radiation protection.
 ...
PMID:Vasoformative non-osteogenic (angio) sarcomas of bone-marrow stroma due to strontium-90. 108 47

Thirty-two children with solid tumors (lymphangioma, fibrosarcoma, hepatocarcinoma, osteogenic sarcoma, rhabdomyosarcoma, lymphosarcoma, mesenchymoma, hepatoma, Ewing's sarcoma, reticulum cell sarcoma, neuroblastoma, Hodgkin's disease, and brain tumors) were studied for alterations in coagulation by means of platelet counts, platelet aggregation, thrombelastogram, procoagulant and antigenic factor VIII, fibrin split products, and antithrombin III level. Results indicated hypercoagulability as shown by abnormally short thrombelastograms and elevated factor VIII levels and platelet counts in approximately one-half of the group. With the exception of increased fibrin split products in a third of the patients, little laboratory or clinical evidence for disseminated intravascular coagulation was seen. Hypercoagulability, as noted in adult carcinoma patients, can also occur in childhood sarcoma patients.
 ...
PMID:Hypercoagulability in childhood cancer. 120 73

Osteosarcomas and rhabdomyosarcomas are vigorously invading tumors. Before they can extravasate to the parenchymal organs and form metastases, they have to adhere to the endothelial cells lining the blood vessels and then penetrate through the endothelium. We show that several human sarcoma cell lines, osteosarcomas HOS, MG-63, U2-OS, and a rhabdomyosarcoma RD, express VLA-4 molecule on their surface and bind to the VCAM-I-expressing activated endothelial cell line Ea.hy 926. The increased sarcoma-cell adhesion could be abolished by treating the sarcoma cells with monoclonal antibodies (MAbs) VLA4 (both alpha- and beta-chain, HP2/1 and 4B4 respectively) or treating endothelial cells with VCAM-I antibody (4B9). Furthermore, we show that sarcoma cells adhere to recombinant soluble VCAM-I protein. On the other hand, these sarcoma cell lines do not express marked amounts of other ligands (such as CDII/18 or sialyl-Lex) for other endothelial adhesion molecules (ICAM-I, ICAM-2, E- and P-selectin) indicating that the VLA-4-VCAM-I dependent pathway might be of major importance in sarcoma extravasation. VLA-4 is not always in an avid form and therefore the expression of VLA-4 does not directly predict adherence to VCAM-I. The avidity of VLA-4 (measured by adherence to soluble VCAM-I) of MG-63 and U2-OS cells could be increased by a 30-min PMA treatment, whereas the avidity of VLA-4 on HOS cells increased only after 48 hr of PMA induction. Our results show that sarcoma cell lines (HOS, MG-63, U2-OS and RD) adhere to stimulated endothelium via VLA-4-VCAM-I adhesion molecules and that VLA-4 avidity on sarcoma cells can be differentially modulated by PMA.
 ...
PMID:VLA-4 integrin on sarcoma cell lines recognizes endothelial VCAM-1. Differential regulation of the VLA-4 avidity on various sarcoma cell lines. 128 Nov 43

Deposition of basement membrane extracellular matrix is influenced by adjacent tumor cells, and in some cases, the pattern of type IV collagen deposit is characteristic in malignant tumors. In this report, we analyzed the difference in type IV collagen deposition patterns between benign and malignant phyllodes tumors (PTs) of the breast. Of the 15 cases of PTs, 8 cases were benign PTs and 7 cases were malignant PTs. Three cases of other primary sarcomas of the breast (stromal sarcoma, angiosarcoma and osteosarcoma) and 2 cases of fibroadenomas were studied for comparison. The malignant PTs were distinguished from benign ones by increased mitotic figures, cellular atypism, and a higher proliferation index of stromal cells. Immunohistochemical staining against type IV collagen in malignant PTs revealed extensive to moderate deposition of type IV collagen around the small blood vessels in duplicate or multilayering pattern, while benign PTs showed minimal deposition in a single linear pattern. All of the three cases of other sarcomas revealed multilayering or meshwork pattern of type IV collagen around the blood vessels. The deposition of type IV collagen around the blood vessels may reflect the malignant behavior of the stromal tumors of the breast.
 ...
PMID:Differential pattern of perivascular type IV collagen deposits in phyllodes tumors of the breast. 129 40

The paper deals with a comparison of basal levels of secretion of total testosterone (T) and estradiol-17 beta (E2), their free and albumin and sex-steroid-binding globulin fractions as well as LH, FSH, prolactin and STH in blood serum of 60 normal height and 60 tall healthy adolescents and those with primary osteogenic sarcoma of bones at different stages of puberty. The study established a significantly higher level of testosterone and free androgen index and a lowered concentration of sex-steroid-binding globulin in blood serum of both normal and tall adolescent patients with osteogenic sarcoma at different stages of puberty. No significant differences were found in said indexes of estrogens between sarcoma patients and a specific group chosen for comparison, as far as physical status is concerned. The role of sex steroid hormones and, particularly, that of androgens in the pathogenetical mechanisms of osteogenic sarcoma growth is discussed.
 ...
PMID:[Sex and pituitary hormone secretion in normal-height and tall adolescents with primary osteogenic sarcoma]. 130 Jul 19

The radiographys of 32 cases with mandible sarcoma were analysed with digital image processing. The processed image of fibrosarcoma showed many scattered fine grains after the X-ray film were edge detected. In the same processing, the image of chondrosarcoma showed many little rings or arc structures. For osteosarcoma, the processed image showed very irregular veins. These digital processing pictures can help us to differentiate mandible sarcomas.
 ...
PMID:[Digital image processing of radiography of 32 cases with mandible sarcomas]. 130 49

The clinical, pathological and radiographic materials of 99 cases with osteosarcoma, fibrosarcoma and chondrosarcoma of the jaws were analyzed comprehensively. Neither obvious differences of age, sex, duration, location of tumor, clinical symptoms and five-year survivals nor radiographic characteristics were found between these three types of sarcoma. The tumor stage and destruction of cortical bone by the tumor are the important factors influencing the prognosis of the patients. The radiographic findings are valuable for the estimation of prognosis.
 ...
PMID:[A comprehensive analysis of osteosarcoma, fibrosarcoma and chondrosarcoma of the jaws]. 130 56


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>